Clinical trial
Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent…
NCT00072566 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00072566 |
|---|---|
| Title | Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer |
| Official title | Phase II Clinical Trial of Bevacizumab (NSC 704865) and Low Dose Oral Cyclophosphamide in Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage IV Ovarian Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis |
| Enrollment | 70 |
| Start date | Dec 1, 2003 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Nov 5, 2003 |
| Last update posted | May 12, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: